{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166105004",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166105004",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for phenprocoumon and CYP2C9",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450921",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450921",
    "name" : "phenprocoumon"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA126",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA126",
    "symbol" : "CYP2C9",
    "name" : "cytochrome P450, family 2, subfamily C, polypeptide 9"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>For patients treated with phenprocoumon, consider checking INR more frequently in individuals with CYP2C9 2*/2*, 2*/3*, or 3*/3* genotype.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on CYP2C9 genotypes [Article:<a href=\"/pmid/21412232\">21412232</a>]. They recommend checking INR more frequently in individuals with CYP2C9 2*/2*, 2*/3*, or 3*/3* genotype.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Genotype </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> CYP2C9 *1/*2 </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> CYP2C9 *2/*2 </td><td> Check INR more frequently </td><td> Published controlled studies of good quality\\* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> CYP2C9 *1/*3 </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> CYP2C9 *2/*3 </td><td> Check INR more frequently </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): death; arrhythmia; unanticipated myelosuppression </td></tr><tr><td> CYP2C9 *3/*3 </td><td> Check INR more frequently </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x10{^}9^/l; leucopenia 1.0-2.0x10{^}9^/l; thrombocytopenia 25-50x10{^}9^/l; severe diarrhea <br/></td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li></ul>"
}